Biktarvy (Bictegravir) has a combination of three antiviral drugs: bictegravir, emtricitabine, and tenofovir alafenamide. This works by preventing the virus from multiplying in the body, thereby reducing the viral load and helping the immune system maintain a better defense against infections. Biktarvy is known for its high efficacy, minimal side effects, and convenience, making it a popular choice for managing HIV-1 infections.
-
Bictegravir: An integrase inhibitor that prevents the HIV virus from integrating into the DNA of human cells, which is essential for viral replication.
-
Emtricitabine: A nucleoside reverse transcriptase inhibitor (NRTI) that interferes with the reverse transcription process, blocking the conversion of viral RNA into DNA.
-
Tenofovir alafenamide: Another NRTI that works similarly to emtricitabine, helping to reduce the amount of HIV in the body.